Expired activity
Please go to the PowerPak homepage and select a course.

Reducing Glycemic Variability in Type 1 Diabetes: An Exploration of Non-Insulin Treatment Options

Jointly provided by the Postgraduate Institute for Medicine and E&S MedEd Group.

Supported by an independent educational grant provided by Sanofi and Lexicon Pharmaceuticals.

Release Date

January 10, 2019

Expiration Date

January 10, 2020


90 Minutes


Endocrinology, Diabetes, and Metabolism
Clinical Lipidology; Nutrition; & Internal Medicine
Campbell County Health

Linda B Haas, PhC, RN, Certified Diabetes Educator (ret)
Diabetes Consultant

Susan Cornell, PharmD, CDE, FAPhA, FAADE
Associate Director of Experiential Education
Associate Professor of Pharmacy Practice, Midwestern University
Diabetes Educator and Care Provider
Bolingbrook Christian Health Clinic
Will-Grundy Medical Clinic

Curtis L Triplitt, PharmD, CDE
Associate Director, Diabetes Research
Texas Diabetes Institute
Clinical Associate Professor
Department of Medicine
Division of Diabetes
University of Texas Health Science Center at San Antonio

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the importance of achieving target A1C and the consequences of long-term hyperglycemia in people with T1DM
  • Describe how the mechanisms of action of newer non-insulin glucose-lowering agents differ from traditional insulin-based therapies
  • Summarize the risks and benefits associated with newer non-insulin glucose- lowering agents in T1DM
  • Identify people with T1DM in whom newer non-insulin glucose-lowering therapy may be appropriate

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and E&S MedEd Group. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-19-474-H01-P
Type of Activity Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Certified Diabetes Educators

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity.

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Speakers' Bureaus: Sanofi Aventis and Janssen Pharmaceuticals, Inc.

Linda B Haas, PhC, RN, Certified Diabetes Educator (ret)
Has nothing to disclose.

Susan Cornell, PharmD, CDE, FAPhA, FAADE
Speaker's Bureau and Advanced Practitioner Advisory Board: Novo Nordisk Inc.

Curtis L. Triplitt, PharmD, CDE
Speakers' Bureaus: Eli Lilly, Boehringer Ingelheim Pharmaceuticals, Janssen, AstraZeneca

Planners and Managers

The PIM planners and managers have nothing to disclose. The E&S MedEd Group planners and managers have nothing to disclose. The AADE planners and managers have nothing to disclose.

Fee Information

There is no fee for this educational activity.

How to Earn Credit

During the period of January 10, 2019 through January 10, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.



Required Computer Hardware/Software

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities